Navigation Links
Emergent and DiFusion Form Strategic Partnership to Take CleanFuze™ Antimicrobial Implants to Market
Date:7/31/2013

Austin, TX (PRWEB) July 31, 2013

Emergent Technologies, Inc., a leading innovation solutions company, and DiFusion Technologies, Inc., a pioneering orthobiologics company, announced today a strategic partnership in which Emergent will assist DiFusion in the launch of its proprietary suite of CleanFuze antimicrobial orthobiologic implants.

CleanFuze implants use DiFusion’s core technology, a novel biomaterial that resists infection and forms a direct and lasting connection with bone. This material uses Metallic Ions as Therapeutic Agents (MITA’s) to effect cellular signaling and both upstream and downstream cellular metabolic processes.

According the Centers for Disease Control and Prevention, hospital infections, including surgical site infections, are the fourth largest killer in the U.S., claiming more U.S. lives than AIDS, breast cancer and traffic accidents combined.

“DiFusion’s proven biofilm inhibition technology and strong patent position are a good fit for our Partner Solutions Model,” said Thomas Harlan, Chairman and CEO of Emergent Technologies. “Utilizing our model will help DiFusion accelerate successful market acceptance and deployment of its CleanFuze technology.”

Derrick Johns, DiFusion Founder and CEO commented, “We look forward to working with Emergent and leveraging the experience and expertise the company has developed over many years of successful technology commercialization and its numerous industry partnerships.”

DiFusion will launch its CleanFuze Xiphos™ spinal implant products in the European Union later this year and is actively seeking strategic distribution partners through its alliance with Emergent. Interested parties should contact Kris Looney at klooney(at)emergenttechnologies(dot)com.

“We are beginning to see stronger than average premarket demand in Europe for the CleanFuze Xiphos product,” said Johns, “and expect this to continue as we expand the CleanFuze platform to include antimicrobial wound care, scaffold carriers, bone growth and tissue regeneration.”

About Emergent Technologies, Inc.
Headquartered in Austin, Texas, Emergent Technologies, Inc. (Emergent) utilizes its innovation-based, partner driven model to identify, manage, develop and bring to market game-changing scientific discoveries. Emergent's diverse business and technical team along with its unique innovation process of transforming scientific breakthroughs into technology platforms with multiple applications, maximizes the value of promising ideas and underutilized intellectual properties without the risk associated with commercial development. Emergent applies its experience and expertise to provide investors, entrepreneurs, and industry partners access to innovative solutions to advance initiatives and protect and grow core businesses with novel, differentiating technology. For more information, visit the Emergent website http://www.emergenttechnologies.com.

About DiFusion Technologies, Inc.
Founded in 2008 in Austin, Texas, DiFusion Technologies, Inc. is a medical device company focused on reducing the rising incidence of surgical site infections in orthopedic and spine surgery through the development of a suite of patented antimicrobial orthobiologic polymeric implants. Initially focusing on the multi-billion dollar spinal implant market, the company has developed a technology with applicability across a variety of orthopedic segments using well characterized implants with benefits for the patient, surgeon, hospital and payer. For more information about DiFusion Technologies, visit http://www.difusiontech.com

Media Contact: Derrick Johns – djohns(at)difusiontech(dot)com

Read the full story at http://www.prweb.com/releases/2013/7/prweb10978531.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Emergent Technologies and Caisson Biotech Form Strategic Alliance with Local Health Care Providers to Improve Delivery and Performance of a Therapeutic Drug
2. Eckert & Ziegler Vitalea Science and Korea-based BioCore Bring Human Microdosing to Korea to Address the Needs of the Emergent Pharmaceutical Industry
3. GlycoVaxyn AG secures CHF 5.1 million Strategic Translation Award from the Wellcome Trust to finance clinical development of Shigella vaccine
4. DuPont Realigns Leadership Team to Accelerate Integrated Science Execution, Explores Strategic Alternatives for Performance Chemicals
5. Pittsburgh Life Sciences Greenhouse Makes Strategic Adjustment To Put Laser Focus On 2013 Goals
6. Alpha Source, Inc. Hires Strategic Sourcing Manager
7. BioLife Solutions Announces Strategic Partnership with HemaCare
8. Paul Knittle Joins Wireless Analytics as Director of Strategic Accounts
9. Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc.
10. Elsevier Signs Strategic Collaboration Agreement with Peoples Medical Publishing House, China
11. VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... A study ... completed in an ambulatory surgery center (ASC) with satisfactory clinical and patient-reported outcomes, ... TDR studies. , Jake Lubinski, president of AxioMed, commented on the recent ...
(Date:2/24/2017)... , Feb. 24, 2017 Provectus Biopharmaceuticals, ... the "Company"), a clinical-stage oncology and dermatology biopharmaceutical ... deadline to participate in its previously announced rights ... of shares of common stock and Series C ... of listed warrants. As previously ...
(Date:2/24/2017)... N.J. , Feb. 24, 2017  Driven ... and biotechnology are now the fastest growing categories, ... Specialty Actives in Personal Care: Multi-regional Market ... research and management consulting firm Kline. ... bioprocesses that make them more effective for skin ...
(Date:2/24/2017)... Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), ... announced its financial results for the fourth quarter and fiscal ... Highlights Total sales in the fourth ... increased by 13.6% in USD terms to $77.6 million from ... Gross profit increased by 13.3% to $46.8 million from ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017  EyeLock LLC, a market leader ... white paper " What You Should Know About Biometrics ... ensuring user authenticity is a growing concern. In traditional ... users. However, traditional authentication schemes such as username/password suffer ... Biometric authentication offers an elegant solution to the problem ...
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
(Date:1/26/2017)...  Acuity Market Intelligence today released the 2017 ...  Acuity characterizes 2017 as a "breakout" year for ... a new understanding of the potential benefits these ... identity are often perceived as threats to privacy ... of Acuity Market intelligence. "However, taken together these ...
Breaking Biology News(10 mins):